David Drewry

David Drewry

SGC UNC

Drewry

David Drewry

(919) 962-5349

Biography

David Drewry is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy. Drewry enjoys running, reading and relaxing with his family at local restaurants, the movie theater or in the kitchen playing board games.

2020

Quantifying CDK inhibitor selectivity in live cells.

Wells CI, Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Ingold MR, Pickett JE, Drewry DH, Pugh KM, Schwinn MK, Hwang BB, Zegzouti H, Huber KVM, Cong M, Meisenheimer PL, Willson TM, Robers MB

Nat Commun. 2020-6-2 . 11(1):2743 .doi: 10.1038/s41467-020-16559-0

PMID: 32488087

HighVia-A Flexible Live-Cell High-Content Screening Pipeline to Assess Cellular Toxicity.

Howarth A, Schröder M, Montenegro RC, Drewry DH, Heba S, Millar V, Müller S, Ebner DV

SLAS Discov. 2020-5-27 . 2472555220923979 .doi: 10.1177/2472555220923979

PMID: 32458721

CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.

Ketley A, Wojciechowska M, Ghidelli-Disse S, Bamborough P, Ghosh TK, Morato ML, Sedehizadeh S, Malik NA, Tang Z, Powalowska P, Tanner M, Billeter-Clark R, Trueman RC, Geiszler PC, Agostini A, Othman O, Bösche M, Bantscheff M, Rüdiger M, Mossakowska DE, Drewry DH, Zuercher WJ, Thornton CA, Drewes G, Uings I, Hayes CJ, Brook JD

Sci Transl Med. 2020-4-29 . 12(541): .doi: 10.1126/scitranslmed.aaz2415

PMID: 32350131

SGC-AAK1-1: A Chemical Probe Targeting AAK1 and BMP2K.

Wells C, Couñago RM, Limas JC, Almeida TL, Cook JG, Drewry DH, Elkins JM, Gileadi O, Kapadia NR, Lorente-Macias A, Pickett JE, Riemen A, Ruela-de-Sousa RR, Willson TM, Zhang C, Zuercher WJ, Zutshi R, Axtman AD

ACS Med Chem Lett. 2020-3-12 . 11(3):340-345 .doi: 10.1021/acsmedchemlett.9b00399

PMID: 32184967

In Depth Analysis of Kinase Cross Screening Data to Identify CAMKK2 Inhibitory Scaffolds.

O'Byrne SN, Scott JW, Pilotte JR, Santiago ADS, Langendorf CG, Oakhill JS, Eduful BJ, Couñago RM, Wells CI, Zuercher WJ, Willson TM, Drewry DH

Molecules. 2020-1-13 . 25(2): .doi: 10.3390/molecules25020325

PMID: 31941153

2019

Binding and structural analyses of potent inhibitors of the human Ca2+/calmodulin dependent protein kinase kinase 2 (CAMKK2) identified from a collection of commercially-available kinase inhibitors.

Profeta GS, Dos Reis CV, Santiago ADS, Godoi PHC, Fala AM, Wells CI, Sartori R, Salmazo APT, Ramos PZ, Massirer KB, Elkins JM, Drewry DH, Gileadi O, Couñago RM

Sci Rep. 2019-11-11 . 9(1):16452 .doi: 10.1038/s41598-019-52795-1

PMID: 31712618

E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition.

Burdova K, Yang H, Faedda R, Hume S, Chauhan J, Ebner D, Kessler BM, Vendrell I, Drewry DH, Wells CI, Hatch SB, Dianov GL, Buffa FM, D'Angiolella V

EMBO J.. 2019-8-19 . e101443 .doi: 10.15252/embj.2018101443

PMID: 31424118

CDK16: the pick of the understudied PCTAIRE kinases.

Axtman A, Drewry D, Wells C

Nat Rev Drug Discov. 2019-7-4 . 18(7):489 .doi: 10.1038/d41573-019-00076-x

PMID: 31267068

A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction.

Drewry DH, Wells CI, Zuercher WJ, Willson TM

SLAS Discov. 2019-4-29 . 2472555219838210 .doi: 10.1177/2472555219838210

PMID: 31034310